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Abstract. circulating microrna (mirna) biomarkers are 
implicated in the diagnosis, monitoring and prediction of various 
disease processes. Before embarking upon biomarker discovery, 
miRNA extraction techniques must first be optimised in the 
biofluid and population under study. Using plasma from a healthy 
pregnant woman, it was attempted to optimise and compare the 
performance of two commercially available mirna extrac‑
tion kits; Qiagen (mirneasy Serum/Plasma) and Promega 
(Maxwell® rSc mirna from Tissue or Plasma or Serum). 
Sample mirna content (concentration and percentage) was 
assessed using agilent Bioanalyzer Small rna chips and reverse 
transcription‑quantitative Pcr (rT‑qPcr) using four consti‑
tutively expressed mirnas (hsa‑mir‑222‑3p, hsa‑let‑7i‑3p, 
hsa‑mir‑148‑3p and hsa‑mir‑30e‑5p). Quality control spike‑ins 
monitored rna extraction (uniSp2, 4 and 5) and cdna 
synthesis (uniSp6, cel‑mir‑39‑3p) efficiency. optimisation 
approaches included: i) Starting volume of plasma; the addition 
of ii) Proteinase K; iii) a rna bacteriophage carrier (MS2); and 
iv) a glycogen carrier. The two kits exhibited equivalence in 
terms of mirna recovery based on Bioanalyzer and rT‑qPcr 
ΔΔcq results. optimisation attempts for both kits failed to 
improve upon mirna content compared with standard meth‑
odology. comparing the standard methodology, the Qiagen kit 
was more consistent (smaller variance of Δcq values) compared 
with the Promega kit. The standard methodology of either kit 
would be suitable for the investigation of mirna biomarkers in 
a healthy pregnant population.
Introduction
Microrna (mirna) are a class of short, non‑coding rnas 
involved in post‑transcriptional downregulation of protein 
expression in eukaryotic organisms, through silencing of target 
messenger rnas (1‑3). They are implicated in regulating 
approximately one third of the genome; controlling multiple 
cellular processes, including apoptosis (2‑4), proliferation (2), 
differentiation (2‑5) and development (3‑6).
an expanding body of pre‑clinical evidence has impli‑
cated altered mirna expression profiles in several disease 
processes (2,5‑10), with the potential to facilitate earlier 
diagnosis, disease monitoring and predict prognosis (3,8‑10). 
increasing literature is emerging concerning the role of 
placental‑derived mirnas in pregnancy, originating from 
three main clusters on chromosome 19 (c19Mc, mir‑371‑3) 
and chromosome 14 (C14MC) (11,12). Altered miRNA profiles 
have been detected in both healthy pregnancy (changing across 
trimesters and compared to the non‑pregnant state) (13‑16) and 
pregnancies complicated by gestational hypertension (17,18), 
pre‑eclampsia (19), diabetes (20,21) or congenital anomalies (22).
Given the potential clinical utility of mirnas, accurate 
and efficient quantification is essential. The relative ease and 
safety of obtaining blood samples over tissue biopsies (23‑25), 
as well as the stability of circulating mirnas has focused 
much of the current research towards blood testing (3,26). 
However, due to the low concentration of free mirnas in 
biofluids, variable findings between different starting media 
(serum vs. plasma) and the alteration of the miRNA profile 
by haemolysis, signalling or environmental exposures, robust 
results have proven difficult to obtain (26‑30). Additionally, 
variability in the collection, storage and processing of samples 
can affect outcomes (27). Standardised procedures for all 
stages of miRNA quantification would minimise variability 
but are yet to be developed. Techniques that increase efficiency 
are favoured, as higher mirna concentrations in the eluate 
facilitate quantification (27,31). mirna extraction from 
biofluids is the prime source of intra‑assay variation in miRNA 
quantification, highlighting the need for a robust, reproducible 
protocol (32‑34).
To assist in mirna extraction, there are several commer‑
cially available kits, yet many pre‑clinical biomarker studies 
fail to acknowledge the variability introduced by these 
different methodologies, potentially contributing to poor repli‑
cability between studies and delaying progression into clinical 
practice. There is a paucity of literature concerning the optimal 
kit to answer the clinical question at hand, as media and kit 
Comparison and optimisation of microRNA extraction 
from the plasma of healthy pregnant women
VicToria l. ParKer1,  BrYonY F. cuSHen1,  eleFTHerioS GaVriil1,  BenJaMin MarSHall1,   
SaraH WaiTe1,  allan PaceY1  and  Paul r. HeaTH2
1Department of Oncology and Metabolism, The University of Sheffield, Sheffield S10 2SF;  
2Sheffield Institute of Translational Neuroscience, The University of Sheffield, Sheffield S10 2HQ, UK
received July 25, 2020;  accepted december 15, 2020
doi:  10.3892/mmr.2021.11897
Correspondence to: dr Victoria l. Parker, department of 
oncology and Metabolism, The university of Sheffield, level 4, The 
Jessop Wing, Tree root Walk, Sheffield S10 2SF, uK
e‑mail: v.parker@sheffield.ac.uk
Key words: microrna, Homo sapiens, extraction, optimisation, 
pregnancy, women
ParKer et al:  coMPariSon oF microrna eXTracTion KiTS uSinG PlaSMa FroM HealTHY PreGnanT WoMen2
performance may vary between the patient population (males, 
females, pregnant or non‑pregnant) and the disease state under 
investigation (25,35). compounded by inter‑patient variability 
within study samples, identifying the optimal methodology is 
extremely difficult (27,32,36,37). Factors including the starting 
volume of biofluid, use of glycogen, yeast or bacteriophage 
rna carriers (e.g. MS2) and the addition of a serine protease 
(e.g. Proteinase K) to digest native proteins can all be modified 
to improve the yield and reproducibility of mirna extrac‑
tion (24); the effect of each being dependent on the extraction 
technique (24,31,38‑42). carriers are particularly useful when 
handling biofluids with low starting miRNA concentrations 
(e.g. human serum and plasma), as counterproductively, the 
extraction process itself loses a sizeable proportion of the 
sample mirna content (39). downstream analysis techniques 
may restrict the choice of carrier, as degraded rna bacterio‑
phages cannot be distinguished from sample rna content 
using next Generation Sequencing platforms (43), hence 
mirna‑free glycogen carriers are instead recommended for 
this application (43).
This study aimed to compare the relative efficiency of two 
commercially available mirna extraction kits to determine the 
most suitable approach using human plasma derived from women 
with an uncomplicated, healthy pregnancy. Qiagen mirneasy 
Serum/Plasma kit uses a well‑known chloroform/phenol and 
column‑based mirna extraction system, whilst the Promega 
Maxwell® rSc mirna from Tissue or Plasma or Serum kit 
employs a novel technique involving an automated paramag‑
netic particle mover to drive the rna through binding, washing 
and elution steps. To our knowledge, in the published literature, 
a methodological investigation involving this patient group has 
never been performed, neither has a comparison of these two 
particular extraction kits. We additionally sought to optimise 
the performance of each kit through four methodological modi‑
fications varying the: (i) starting volume of plasma; the addition 
of (ii) Proteinase K; (iii) a rna bacteriophage carrier (MS2); 
and (iv) a glycogen carrier.
Materials and methods
Sample collection. Blood was obtained from a healthy preg‑
nant woman with an uncomplicated, low‑risk pregnancy at 
9 weeks' gestation using 4.5 ml Sodium citrate vacutainer tubes 
(nHS Supply chain). Standard venepuncture procedures were 
followed, according to the national cancer institute early 
detection research network, involving a 21‑gauge needle 
to minimise haemolysis. Following collection, samples were 
kept upright and stored on ice (maintaining a temperature of 
~4˚C) to inhibit miRNA degradation by circulating RNases 
within whole blood and processed within 2 h. Samples were 
centrifuged at 1,900 x g for 10 min at 4˚C with the recovered 
plasma supernatant aliquoted and immediately stored at 
‑80˚C. Following gentle thawing at room temperature, aliquots 
underwent a second centrifugation step (16,000 x g for 10 min 
at 4˚C) to generate platelet poor plasma.
Ethical approval. Written patient consent was taken from 
participants, within the ethical approval obtained from the 
united Kingdom north east newcastle and north Tyneside 1 
nHS research ethics committee (reference 16/ne/0292) on 
30/08/2016 and The Health research authority on 27/09/2016, 
with approved non‑substantial (18/10/2018 and 01/05/2019) 
and substantial (12/12/2019) amendments (Table ii).
miRNA extraction. mirna was extracted from plasma 
samples using the: i) mirneasy Serum/Plasma kit (217184; 
Qiagen) and ii) a prototype of the Maxwell® rSc mirna 
from Tissue or Plasma or Serum kit (aS1680; Promega) (44) 
both with minor modifications. Standard manufacturer and 
optimised approaches were performed, modifying: i) starting 
volume of plasma; the addition of ii) Proteinase K; iii) a 
rna bacteriophage carrier (MS2); and iv) a glycogen carrier 
(Figs. 1 and 2; Table i). in short, step (2) of the mirneasy 
protocol was modified; UniSp2, UniSp4 and UniSp5 spike‑in 
mix (reconstituted according to manufacturers' instructions) 
(339390, rna spike‑in kit; Qiagen) (Table ii) was diluted 1:11 
into Qiazol lysis buffer, mixing thoroughly. 0.5 µl of spike‑in 
mix was added per 100 µl of plasma in accordance with the 
manufacturer's protocol. When required (Fig. 2; Table i), 
1 µg per 200 µl of rna bacteriophage MS2 (0.8 µg/µl) 
(10165948001; roche diagnostics GmbH) or 2 µg per 200 µl 
of rna grade Glycogen (20 mg/ml) (r0551; Thermo Fisher 
Scientific, Inc.) was added to the dilute RNA spike‑in and 
Qiazol lysis reagent mix, combining thoroughly. This mix 
was combined with the remaining volume of lysis buffer and 
step (4) of the protocol omitted.
The prototype Promega protocol with minor modifica‑
tions was conducted as follows: lyophilised dnase i was 
resuspended with 275 µl of nuclease free water, adding 5 µl 
of Blue dye as a visual indicator, inverting or swirling to 
mix. Aliquots were produced, storing at 4˚C (few weeks) 
or ‑20˚C (longer storage). UniSp2, UniSp4 and UniSp5 
spike‑in mix (reconstituted according to manufacturers' 
instructions) (339390, rna spike‑in kit, Qiagen) was diluted 
1:11 into binding buffer. 0.5 µl of spike‑in mix was added 
per 100 µl of plasma in accordance with the manufacturer's 
protocol. When required (Fig. 2; Table i), 1 µg per 200 µl 
of rna bacteriophage MS2 (0.8 µg/ µl) (10165948001; 
roche diagnostics GmbH) or 2 µg per 200 µl of rna grade 
Glycogen (20 mg/ml) (R0551; Thermo Fisher Scientific, Inc.) 
was added to the diluted spike‑in mix, combining thoroughly. 
The spike‑in +/‑ carrier molecule mix was then added to the 
remaining volume of binding buffer, mixing thoroughly. 100, 
200 or 500 µl (Fig. 1; Table i) of pre‑processed plasma (see 
Sample collection in Materials and methods section) was 
transferred to a 1.5 ml eppendorf and 60 µl Proteinase K 
added, replacing Proteinase K with nuclease‑free water 
when required (Fig. 2; Table i). This was then added to the 
binding buffer, spike‑in +/‑ carrier molecules mix, vortexing 
for 10 sec. This sample lysate was then incubated at 37˚C 
for 15 min. during this time, the Maxwell® rapid Sample 
concentrator (rSc) cartridges were loaded into the rSc 
deck tray, their seals removed, and the rSc plungers inserted 
into well 8 of the cartridges. 500 µl elution tubes were loaded 
into the deck and 60 µl nuclease‑free water added to each. 
Ten microliters of reconstituted dnase i was added to well 
4 (yellow) of the cartridges and following incubation, all of 
the sample lysate was transferred into well 1 of the cartridges. 
The Maxwell® rSc instrument (aS4500; Promega) (45) 
instrument and the ‘rSc mirna Tissue’ method was used to 
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begin the automated purification run. Following processing, 
the eluate was stored at ‑80˚C.
Five replicates were performed for each approach investi‑
gated. extracted rna was assessed for quality and quantity 
[mirna/small rna ratio (%) and mirna concentration 
(pg/ µl)] using an agilent Small rna chip (5067‑1548; 
agilent Technologies) and 2100 Bioanalyzer (G2939Ba; 
agilent Technologies) according to manufacturers' instruc‑
tions.
miRNA quantification. cdna was synthesised using the 
mircurY lna rT kit (339340; Qiagen) with a total reac‑
tion volume of 10 µl and a minor modification. Specifically, 
during step (2), 0.5 µl of uniSp6 and cel‑mir‑39‑3p spike‑in 
mix, (339390, rna spike‑in kit; Qiagen) (Table ii) was 
diluted 1:5 in nuclease free water and added to the rT reaction 
mix. reverse transcription‑quantitative Pcr (rT‑qPcr) was 
performed using the mircurY lna® SYBr® Green Pcr 
kit (339346; Qiagen) and 14 mirna primers (Table ii). To 
Table i. Standard and optimised microrna extraction approaches.
Kit approach code Plasma volume, µl Proteinase K, µl MS2, µg Glycogen, µg
Promega S a 500 60 none none
 o B 500 replaced with nFH2o none none
 o c 500 60 2.5 none
 o d 500 replaced with nFH2o 2.5 none
 o e 500 60 none 5
 o F 500 replaced with nFH2o none 5
 o G 200 60 none none
 o H 100 60 none none
Qiagen o B 200 none none none
 o c 200 24 1 none
 S d 200 none 1 none
 o e 200 24 none 2
 o F 200 none none 2
 o G 200 24 none none
 o i 100 none 0.5 none
S, standard approach following manufacturers’ instructions/protocol as detailed in manuscript; o, optimised approach; nFH2o, nuclease‑free water.
Table ii. description of the 14 mirna primers used for reverse transcription‑quantitative Pcr.
mirna primer Function Sequence (5'‑3')
UniSp2 RNA extraction efficiency Unavailable
UniSp4 RNA extraction efficiency Unavailable
UniSp5 RNA extraction efficiency Unavailable
UniSp6 cDNA synthesis efficiency Unavailable
cel‑miR‑39‑3p cDNA synthesis efficiency UCACCGGGUGUAAAUCAGCUUG
hsa‑mir‑451a Stably expressed mirna used for aaaccGuuaccauuacuGaGuu
 normalisation and detection of haemolysis
hsa‑mir‑23a Stably expressed mirna used for aucacauuGccaGGGauuucc
 normalisation and detection of haemolysis
hsa‑mir‑423‑3p Stably expressed mirna used for normalisation aGcucGGucuGaGGccccucaGu
hsa‑mir‑103a‑3p Stably expressed mirna used for normalisation aGcaGcauuGuacaGGGcuauGa
hsa‑mir‑191‑5p Stably expressed mirna used for normalisation caacGGaaucccaaaaGcaGcuG
hsa‑mir‑222‑3p Stably expressed mirna of interest aGcuacaucuGGcuacuGGGu
hsa‑let‑7i‑3p Stably expressed mirna of interest cuGcGcaaGcuacuGccuuGcu
hsa‑mir‑148‑3p Stably expressed mirna of interest ucaGuGcaucacaGaacuuuGu
hsa‑mir‑30e‑5p Stably expressed mirna of interest uGuaaacauccuuGacuGGaaG
mirna/mir, microrna.
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minimise run‑to‑run variation, one replicate for each extrac‑
tion approach (Table i) was combined with every primer 
in duplicate upon each 384‑well plate. a 2‑step cycling 
qPCR protocol (95˚C for 2 min followed by 40 cycles at 
95˚C for 10 sec and 56˚C for 60 sec) was conducted using a 
Bio‑rad cFX96, real‑time c1000 Touch Thermal cycler 
(Bio‑rad laboratories, ltd.). rT‑qPcr involved no‑template 
controls (no rna template nor uniSp6/cel‑mir‑39‑3p 
spike‑ins) (nTc) run with all 14 primers and no‑reverse 
Transcriptase controls (nrTc) run with the hsa‑mir‑222‑3p 
mirna primer. inhibition controls (no rna template but 
uniSp2, 4 and 5 or uniSp6/cel‑mir‑39‑3p spike‑ins added) 
were also prepared to exclude spike‑in contamination and run 
with mirna primer hsa‑mir‑222‑3p. replicates QG1 and 
QB1 run with mirna primer hsa‑mir‑451 were selected as 
inter‑plate calibrators (iPc), and performed in duplicate upon 
each 384‑well plate.
Data analysis
Outliers. cq values were calibrated between plates using iPc 
as described by TaTaa (46). Mean cq values and variance 
of duplicates performed for each extraction approach were 
Figure 1. Pictorial scheme depicting the approaches to optimise plasma input volume. PK, proteinase K.
Figure 2 Pictorial scheme depicting the optimisation approaches using PK and the carriers MS2 and glycogen. PK, proteinase K.
Molecular Medicine rePorTS  23:  258,  2021 5
calculated for the 14 miRNA primers. Outliers were identified 
and excluded (n=25) based upon a PCR efficiency of 1.9 for the 
mircurY lna® SYBr® Green Pcr kit and the anticipation 
of increasing cq variance with decreasing mirna concentra‑
tion (47) (Table iii).
Quality control. RNA extraction efficiency was measured 
using a uniSp2, 4 and 5 spike‑in mix, whereby the concentration 
of uniSp2>uniSp4>uniSp5 with a 100‑fold magnitude change 
each time. Variance <2‑3 cqs within each dataset and Δcq of 
5‑7 between spike‑ins was desired. cDNA synthesis efficiency 
markers (uniSp6 and cel‑mir‑39‑3p) were expected to have a 
target variance <2 cqs. Haemolysis levels were measured by 
Δcq = mean cq hsa‑mir‑23a‑mean cq hsa‑mir‑451, whereby 
Δcq >5 or >7 indicated possible vs. high‑risk of haemolysis, 
respectively, as guided by the manufacturer (23).
Relative expression. For each approach under inves‑
tigation, normalisation was performed by calculating the 
geometric mean of three stably‑expressed mirnas in plasma, 
(hsa‑mir‑423‑3p, hsa‑mir‑103a‑3p and hsa‑mir‑191‑5p). 
relative quantification was based upon the ΔΔcq 
method (48), whereby the standard manufacturer's approach 
(a and d; Table i) was used as the control comparator for 
Promega and Qiagen samples respectively. Fold change was 
calculated by 2(‑ΔΔcq) and confidence intervals of ΔΔcq log 
transformed by 2‑(ΔΔCq+/‑confidence interval) (48).
Statistical analysis. Data were first checked for normality 
(Shapiro‑Wilk test). For two‑way comparisons (e.g. Bioanalyzer 
data), if the Gaussian distribution was satisfied, unpaired 
t‑tests with Welch's correction (due to unequal standard devia‑
tions in the populations being compared) were performed, else 
the Mann‑Whitney U test was used. For ≥3‑way comparisons 
(e.g. comparing multiple approaches), Welch's anoVa and 
post hoc dunnett's T3 multiple comparisons test were used. 
Statistics were performed in GraphPad Prism version 8, with 
P<0.05 deemed statistically significant.
Results
Bioanalyzer data. mirna concentration and percentage did 
not significantly differ between the standardised or optimised 
Promega and Qiagen extraction approaches [a‑i (Table i)] 
(P=0.09 and P=0.94, respectively, unpaired t‑test with Welch's 
correction) (Fig. 3).
qPCR data
Quality control. Studying the Promega approaches, fold 
changes between the rna extraction efficiency spike‑ins 
were higher than desired, with uniSp4‑uniSp2 of 8.05, 
uniSp5‑uniSp4 of 5.63 (target 5‑7) (Fig. 4a) and variance 
within the spike‑ins ranging between 2.96 and 5.26 cqs (target 
<3 cq) (Fig. 4B). The Qiagen approaches were generally more 
in range, with uniSp4‑uniSp2 of 6.69, uniSp5‑uniSp4 of 
7.88 (target 5‑7) (Fig. 4a) and variance within the spike‑ins 
ranging between 0.72 and 1.90 cqs (target <3 cq) (Fig. 4B). 
in both kits, uniSp6 cq values were higher in the nTcs 
compared to samples (Promega P=0.0006; Qiagen P=0.0008; 
Mann‑Whitney u test) (Fig. 4c). despite this, a comparison 
of the global mean uniSp6 values across all samples vs. the 
inhibition controls suggested that rna inhibitors did not 
significantly affect the PCR reaction (Promega P=0.07; Qiagen 
P=0.58; Mann‑Whitney U test) (Fig. 4D). This was confirmed 
by comparing the global mean cel‑mir‑39‑3p values across 
all samples vs. cel‑mir‑39‑3p cq values in the inhibition 
controls (Promega P=0.13; Qiagen P=0.52; Mann‑Whitney 
u test) (Fig. 4e). Samples were not haemolysed in any approach 
analysed, with all values <7 (Fig. 4F) (23).
Table III. RT‑qPCR data outlier identification method.
 Maximal acceptable range 












Data shown for RT‑qPCR efficiency of 1.9 (47). RT‑qPCR, reverse 
transcription‑quantitative Pcr.
Figure 3. Bioanalyzer data measuring (a) mirna concentration and 
(B) mirna/small rna ratio (%) for each investigated extraction approach. 
mirna, microrna.
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Comparison of standard vs. optimised approaches. 
i) optimisation of plasma input volume. analysing ΔΔcq 
values across all four mirna of interest (Table ii), only one 
miRNA (hsa‑miR‑222‑3p) revealed a significant difference 
between plasma input volumes using the Promega extraction 
kit (Welch's anoVa test W=10.58, P=0.02). upon post‑hoc 
analysis, a significant difference existed between the two opti‑
misation approaches: 200 µl input + proteinase K, no carriers 
(approach G; Table i) vs. 100 µl (+ proteinase K, no carriers, 
approach H), P=0.02 (dunnett's T3 multiple comparisons test). 
no significant difference was found between the standard 
Qiagen mirna extraction approach using 200 µl plasma [no 
proteinase K + MS2, (approach d)] vs. an optimised approach 
using 100 µl plasma [no proteinase K + MS2, (approach i)], 
with P>0.05 in all comparisons (Fig. 5).
comparing Promega and Qiagen kits using all input 
volumes revealed a significant difference in only one miRNA 
(hsa‑mir‑222‑3p) (Welch's anoVa test W=6.47, P=0.01), with 
a significant post‑hoc analysis for the comparison between 
Promega 100 µl [+ proteinase K, no carriers, (approach H)] 
and Qiagen 200 µl [+ proteinase K, no carriers, (approach G)] 
(P=0.02, dunnett's T3 multiple comparisons test) (Fig. 5).
Figure 4. Quality control analysis. (A) Raw Cq values (mean ± SD) for miRNA extraction efficiency markers (UniSp2, 4 and 5) and cDNA efficiency markers 
(uniSp6 and cel‑mir‑39‑3p). a 5‑7‑fold ΔCq between UniSp2‑UniSp4 and UniSp4‑UniSp5 was anticipated. (B) Variance of RNA extraction efficiency 
markers (target <3 Cq) and cDNA efficiency markers (target <2 Cq). (C) Comparison of raw Cq values (median + 95% confidence interval) for global UniSp6 
levels contained within samples vs. nTcs (P=0.0006 Promega; P=0.0008; Qiagen; Mann‑Whitney u test). (d) comparison of raw cq values (median + 95% 
confidence interval) for global UniSp6 levels contained within samples vs. inhibition controls (Promega P=0.07; Qiagen P=0.58; Mann‑Whitney U test). 
(E) Comparison of raw Cq values (median + 95% confidence interval) for global cel‑miR‑39‑3p levels contained within samples vs. inhibition controls 
(Promega P=0.13; Qiagen P=0.52; Mann‑Whitney u test). (F) Haemolysis analysis for each approach under investigation (samples with Δcq >7 represent a 
high‑risk of haemolysis). *P<0.05 (Mann‑Whitney u test). nTc, no template control; ic, inhibition control; mirna, microrna.
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ii) optimisation using Proteinase K, carriers MS2 and 
Glycogen. comparing ΔΔcq from the standard [500 µl 
input + proteinase K, no carriers, (approach a)] vs. optimised 
approaches for the Promega kit, two mirnas of interest 
showed significant changes (hsa‑miR‑148‑3p, Welch's ANOVA 
test W=17.29, P=0.0006 and hsa‑mir‑222‑3p, W=3.87, 
P=0.046). using hsa‑mir‑148‑3p, post‑hoc analysis revealed 
a significant difference comparing approach e (500 µl 
input + proteinase K + Glycogen) vs. approach F (500 µl 
input, no proteinase K + Glycogen) (P=0.04, dunnett's T3 
multiple comparisons test); and approach c (500 µl input + 
proteinase K + MS2) vs. approach F (P=0.048, dunnett's T3 
multiple comparisons test). For hsa‑mir‑222‑3p, all post‑hoc 
comparisons were not significant (P>0.05). optimisation 
approaches using the Qiagen kit were not significant (P>0.05 
in all comparisons) (Fig. 6). as none of the optimisation 
approaches performed upon either Promega or Qiagen kits 
improved upon the performance of standard approaches, 
further comparisons between kits were not performed.
Comparison of standard approaches Promega vs. Qiagen. 
a comparison between ΔΔcq values for the Promega stan‑
dard approach [500 µl input + proteinase K, no carriers, 
(approach a)] vs. that of the Qiagen kit [200 µl input, no 
proteinase K + MS2, (approach d)] revealed no difference in 
performance across the four mirna of interest (P>0.05).
To determine which kit yielded more consistent rT‑qPcr 
results, the standard deviations of the Δcq values for each 
mirna were compared, using the standard approaches for 
each kit. Three out of four miRNAs were significantly different 
(let‑7i‑3p, P=0.03, hsa‑mir‑30e‑5p, P<0.0001, mir‑222‑3p, 
P=0.003, unpaired t‑test with Welch's correction), with higher 
variances observed with the Promega kit (Fig. 7).
Discussion
The literature surrounding the optimal plasma mirna 
extraction kit for use in a healthy, low‑risk pregnant 
population is extremely limited, yet pre‑clinical biomarker 
studies continue to be published, seemingly precluding 
adequate investigation of this crucial preliminary step. This 
study, comparing standard manufacturer's methodology 
with attempts to optimise the efficiency of the Qiagen 
mirneasy Serum/Plasma kit and the Promega Maxwell® 
rSc mirna from Tissue or Plasma or Serum kit, has 
revealed equivalent performance across the majority 
of parameters investigated, including Bioanalyzer and 
rT‑qPcr comparisons. Specifically, mirna percentage, 
Figure 5. effect on the four mirnas of interest when varying the input volume of plasma (standard vs. optimised approaches) for the Promega and Qiagen 
mirna extraction kits. data are shown as the mean ± standard deviation. *P<0.05 (post hoc dunnett’s T3 multiple comparisons test following Welch’s 
anoVa). mirna/mir, microrna.
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concentration and the ΔΔcq values of four stably 
expressed mirnas of interest using rTqPcr were not 
significantly different when comparing the kits in terms of 
their standardised vs. optimised methodologies. However, 
a difference did emerge concerning the consistency of 
the two kits, with the standard Qiagen mirneasy method 
producing lower Δcq standard deviation values for three 
out of four mirnas under study.
attempts to optimise the individual performance of the 
Qiagen kit were conclusively unsuccessful (no mirnas 
differed), whilst at first glance, this may appear less 
definitive for the Promega kit, with 1‑2 miRNAs differing 
between approaches. crucially, however, none of the 
optimisation approaches approved upon standard manufac‑
turer's protocol, with differences only existing between the 
optimisation approaches themselves (200 vs. 100 µl input 
Figure 6. impact on the four mirnas of interest when varying the use of Proteinase K, carrier molecules MS2 and glycogen (standard vs. optimised approa‑
ches) for the Promega and Qiagen mirna extraction kits. data are shown as the mean ± standard deviation. *P<0.05 (post hoc dunnett’s T3 multiple 
comparisons test following Welch’s anoVa). mirna/mir, microrna.
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volume; Proteinase K use in the presence of a glycogen 
carrier; or, the use of MS2 vs. glycogen). Proteinase K is 
a serine protease; functioning to digest native proteins 
within the sample, including nucleases, whilst lacking 
harmful dnase or rnase activity. interestingly, subtracting 
this enzyme (approach B) from the standard manufac‑
turer's approach (a), did not affect ΔΔcq values across 
the four mirna of interest, potentially suggesting that it 
could be removed without adverse effect. However, given 
the known differences in nuclease content and sample 
quality, particularly when using different human samples, 
it would be wise to retain this step to maximize mirna 
recovery. regarding input volume for the Promega kit, 
lower ΔΔcq values were obtained using a plasma volume of 
100 vs. 200 µl for hsa‑mir‑222‑3p, potentially suggesting 
that the kit performed more efficiently using lower starting 
volumes. However, this finding was not replicated amongst 
the remaining three mirnas of interest. Previous studies 
using the miRNeasy biofluids kit found that doubling the 
input plasma volume (from 100 to 200 µl) does not equate 
to a proportional increase in mirna recovery (24), due 
to protein clogging or saturation of the elution column, 
although others have failed to replicate this finding (49). It 
is possible that these inter‑study disparities reflect the use of 
differing mirna of interest and the varying ability of the 
kit to recover these molecules. The only way to subvert this 
and conclude definitively would be to use a miRNA panel, 
analysing many more different mirnas simultaneously.
The unsuccessful optimisation of the standard Qiagen 
mirneasy protocol is in contrast with previously published 
literature using human plasma samples, suggesting that mirna 
recovery was improved by carriers such as glycogen (50) or 
yeast (42,51). However, one of these studies used pig instead of 
human plasma for the kit optimisation experiments, failing to 
re‑test the findings upon human samples; a precarious assump‑
tion given the known variability in media and kit performance 
between different species and disease states (25,35). 
Meanwhile, others have employed the mirneasy kit with 
the addition of glycogen (24) or low‑dose yeast carriers (52) 
without first establishing whether this modification outper‑
forms standard methodology. Furthermore, a different patient 
population was used within each of these studies, (patients 
with inflammatory bowel disease, colorectal adenomas, or 
healthy controls), rendering comparisons impossible.
To our knowledge this is the first published comparison of 
the Qiagen mirneasy serum/plasma and Promega Maxwell® 
rSc mirna from Tissue or Plasma or Serum kit. Previous 
literature has compared the performance of the mirneasy 
serum/plasma kit to other commercially available products, 
finding variable results; mirneasy yielded one of highest 
mirna yields and purity (42,53,54) being highly reproduc‑
ible with minimal inter‑operator variability (51) vs. mirneasy 
outperformed (24,52,55) or comparable performance (56). 
again, this is likely due to differences in the patient population 
under study (healthy vs. diseased, males vs. females of different 
ages), rna input volume and the number of technical replicates 
performed (49), with lower number of replicates and high tech‑
nical variance being associated with false significant levels (24).
The Promega extraction kit uses a new, automated para‑
magnetic mirna extraction technique which confers many 
advantages over traditional methods, not least minimizing the 
risks of sample cross‑contamination; safety concerns associated 
with the handling of chemicals such as chloroform and phenol; 
issues surrounding column saturation or protein clogging; and 
technical variability between runs. Furthermore, the approach 
is highly efficient and enables 16 samples to be processed 
simultaneously within 70 min, which cannot be achieved using 
other commercially available kits (e.g. mirneasy), largely due 
to protocol time limits, particularly within the column‑based 
rna binding, washing and elution steps. during this study, 
the authors could simultaneously process only 8‑10 samples 
using the mirneasy kit, with a processing time of ~120 min. 
Higher simultaneous sample processing is particularly 
advantageous for studies involving large sample numbers, 
where rapid throughput on this preliminary step is essential. 
additionally, the increased elution volume using the Promega 
kit (60 vs. 14 µl) is certainly advantageous to downstream 
applications, enabling more experimental investigations and 
replicates to be conducted with each individual sample, while 
facilitating standardisation between experiments and batch 
calibration. lower elution volumes have been suggested to 
generate more concentrated samples (42), however this study 
and others have not found this (24). A final consideration is the 
financial cost, with the per sample cost being slightly lower 
with the Promega kit (£6.88 vs. £7.80 as of June 2020). Given 
the automated Promega protocol and reduced user‑input, the 
Figure 7. consistency comparison. comparing the Δcq standard devia‑
tions for the Promega and Qiagen kits across the four mirnas of interest. 
Data are shown as the mean + 95% confidence interval except when β then 
median + interquartile range (non‑Gaussian distribution). *P<0.05 (unpaired 
t‑test with Welch’s correction). mirna/mir, microrna.
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increased variance of the standard methodology compared 
to the Qiagen kit was surprising and could represent a batch 
extraction issue, as these samples were extracted separately to 
the other optimisation approaches.
The rna extraction efficiency spike‑ins within the 
Promega approaches generated higher than expected 
cq values, which could be explained by the high degree of 
variance introduced by the different optimisation techniques, 
rather than the presence of rnase contamination. This is 
supported by the high variance observed within the individual 
spike‑in data for uniSp2, 4 and 5. However, further repeat 
experiments, potentially involving additional purification 
steps would be needed to confirm or refute this. We concur 
that the validity of this study was not diminished by the 
suggestion of cdna synthesis inhibitors within the quality 
control analysis. Firstly, these inhibitors did not significantly 
impair the rT‑qPcr upon statistical analysis and secondly, 
such quality control indicators are designed for samples 
extracted using the same standardised methodology, which 
was not the case in this study. it is clear that some optimisation 
approaches (e.g. H in Promega), were detrimental to mirna 
extraction, generating cq values >40 and hence the return of 
‘no data’ for several replicates, which would have raised the 
variance of the quality control markers. The same applies for 
the rna extraction quality control spike‑ins. a limitation of 
this study is that a like‑for‑like comparison could not be made 
using the automated mirna extraction system manufactured 
by Qiagen; (Qiacube, 9001793), and further studies should 
address this. Given the inter‑individual variation within human 
samples (57), further work should include repeating these 
experiments using samples taken from several individuals 
to validate the findings. The equivalent performance of the 
two extraction kits sampled within this study, suggests that 
either would be suitable when evaluating or setting up studies 
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